Responses
Late-breaking abstracts
Checkpoint blockade therapy
786 Distinct efficacy and immunological responses to aPD-1, aPD-L1 and aPD-L2 immunotherapy in B16 melanoma in aged versus young hosts includes T-cell stem cell effects and PD-L2 expression differences
Compose a Response to This Article
Other responses
No responses have been published for this article.
